Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-019 in advanced malignant tumors
NCT05223231Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LBL-019 in cancer, sponsored by Leads Biolabs. Primary endpoint: Safety and Tolerability at 24 months. Started Apr 2022; status: completed.
02
Drugs
LBL-019
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05223231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223231.